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Background: Modaﬁnil, a putative cognitive enhancing drug, has previously been shown to improve
performance of healthy volunteers as well as patients with attention deﬁcit disorder and schizophrenia,
mainly in tests of executive functions. The aim of this study was to investigate the effects of modaﬁnil on
non-verbal cognitive functions in healthy volunteers, with a particular focus on variations of cognitive
load, measures of motivational factors and the effects on creative problem-solving.
Methods: A double-blind placebo-controlled parallel design study evaluated the effect of 200 mg of
modaﬁnil (N ¼ 32) or placebo (N ¼ 32) in non-sleep deprived healthy volunteers. Non-verbal tests of
divergent and convergent thinking were used to measure creativity. A new measure of task motivation
was used, together with more levels of difﬁculty on neuropsychological tests from the CANTAB battery.
Results: Improvements under modaﬁnil were seen on spatial working memory, planning and decision
making at the most difﬁcult levels, as well as visual pattern recognition memory following delay.
Subjective ratings of enjoyment of task performance were signiﬁcantly greater under modaﬁnil
compared with placebo, but mood ratings overall were not affected. The effects of modaﬁnil on creativity
were inconsistent and did not reach statistical signiﬁcance.
Conclusions: Modaﬁnil reliably enhanced task enjoyment and performance on several cognitive tests of
planning and working memory, but did not improve paired associates learning. The ﬁndings conﬁrm that
modaﬁnil can enhance aspects of highly demanding cognitive performance in non-sleep deprived
individuals.
This article is part of a Special Issue entitled ‘Cognitive Enhancers’.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Modaﬁnil (Provigil, 1997) is a wake promoting agent of largely
unknown mechanism with demonstrable efﬁcacy in the treatment
of daytime sleepiness associated with narcolepsy (Benerjee et al.,
2004) and shift-work (Czeisler et al., 2005). Modaﬁnil has been
shown to signiﬁcantly improve performance on tests of executive
cognition such as working memory, cognitive ﬂexibility and plan-
ning in non sleep-deprived healthy volunteers (Turner et al., 2003;
Müller et al., 2004; Minzenberg and Carter, 2008; Finke et al., 2010;epartment of Psychiatry (Box
CB2 2QQ, UK. Tel.: þ44 (0)
bjs-sec@medschl.cam.ac.uk
 license.Repantis et al., 2010; Mohamed and Sahakian, 2012) and in patients
with neuropsychiatric disorders (Turner et al., 2004; Turner, 2006;
Minzenberg and Carter, 2008). These pro-cognitive effects of
modaﬁnil are of possible therapeutic importance given its low
liability for abuse (Deroche-Gamonet et al., 2002), lower risk of
adverse effects on the cardiovascular system (Makris et al., 2004;
Lynch et al., 2009) and lack of anxiogenic effects that may occur
with typical stimulant drugs such as dexamphetamine (Simon
et al., 1994).
Turner et al. (2003) originally showed that a single oral dose of
modaﬁnil (100 mg or 200 mg) signiﬁcantly improved performance
on tests of digit span, visual recognition memory, visuospatial
planning, and stop-signal reaction time (SSRT), but not self-ordered
spatial working memory (SWM) in healthy volunteers. The same
doses also lengthened response times in tests of decision making,
delayed matching to sample, and visuospatial planning, suggesting
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inconsistent with this interpretation, whilst still obtaining reliable
cognitive enhancing effects (Müller et al., 2004; Marchant et al.,
2009; Winder-Rhodes et al., 2010). Some studies have failed to
ﬁnd robust cognitive enhancing effects on performance of mod-
aﬁnil using similar tests, although some of thesewere ﬂawed due to
insufﬁcient statistical power (see Randall et al., 2005).
In order to address these issues, the present study used a single
dose of modaﬁnil 200 mg (Turner et al., 2003; Minzenberg et al.,
2008) in a placebo-controlled double-blind design with non
sleep-deprived healthy volunteers.
There were three key advances on previous work: First, varia-
tions of the cognitive tests which utilised awider range of cognitive
load or task difﬁculty were employed, in the case of three ‘CANTAB’
tests: self-ordered spatial working memory (SWM); one-touch
‘Stockings of Cambridge’ (SoC) test of planning; and the test of
visuospatial paired-associates learning (PAL). Performance
improvements in the more difﬁcult task conditions were predicted.
Second, we investigated if previously established effects on non-
verbal on memory and executive functions could be extended to
non-verbal ‘creative’ reasoning, using tasks similar to those adop-
ted in a study of effects of amphetamine by Farah et al. (2009).
Finally, we also employed subjective measures of performance, as
well as standard analogue mood and cardiovascular indices,
because of suggestions that modaﬁnil might inﬂuence cognition in
part through possible effects on motivation or arousal. Our cogni-
tive tasks were selected so that we could test the hypothesis of
cognitive enhancing effects of a single dose of modaﬁnil in healthy
participants without sleep deprivation.
2. Methods
2.1. Participants
Sixty four healthy male (n ¼ 31) and female (n ¼ 33) volunteers (mean
age  SD ¼ 25.34  3.95, range 19e36 years) were identiﬁed via the University of
Cambridge Behavioural and Clinical Neuroscience Institute subject panel and via
local advertisements. All participants were screened by an experienced psychiatrist
(UM) or neurologist (JBR). Subjects were excluded if they had any signiﬁcant
psychiatric history, visual or motor impairment or the concurrent use of any
psychotropic medications or any medication contra-indicated with modaﬁnil. In
addition, participants with a history of hypertension, cardiac disorders, epilepsy,
drug or alcohol abuse were also excluded. All subjects were advised not to consume
alcohol or caffeine for 12 h before the testing sessions. All participants were ques-
tioned about compliance with alcohol and caffeine restrictions before inclusion into
the study. Smoking history was not recorded but as subjects were randomly allo-
cated to the two groups, there should have been no difference between groups. A
light breakfast or snack and juice were allowed before, but not during, the experi-
mental session. Each participant gave awritten consent prior to testing and received
monetary compensation of £25 plus local transport expenses.
2.2. Research governance
The protocol was approved by the Cambridge Local Research and Ethics
Committee (LREC No. 10/H0305/39) and exempted from clinical trial status by the
Medicines and Health Care Products Regulatory Agency (MHRA), London, the
national drug licensing agency.
2.3. Pharmacological design
This was a randomised, placebo controlled and double-blind study with
a parallel group design, deliberately chosen to avoid problems with practice effects
that are common in studies with crossover subjects design on tasks of executive and
memory functions.
Participants were randomly allocated to one of two blinded medications:
modaﬁnil or placebo. This allowed us to control the matching of parallel groups in
the course of the study. In order to balance drug conditions for gender, males and
females were separately randomised for medications. Unblinding of the medication
followed after the data analysis. All volunteers were asked to spend thewaiting time
with low arousing activities (reading, watching TV or napping) in a day room and
were monitored by research nurses. Cognitive testing stated 2 h after drugadministration in a silent consultation room at theWellcome Trust Clinical Research
Facility at Addenbrooke’s Centre for Clinical Investigation.
2.4. Procedure
Subjects completed questionnaires assessing mood and creativity (Visual
Analogue Scale, Bond and Lader, 1974; Gough, 1979) and were tested for verbal IQ
(National Adult Reading Test, Nelson and Willison, 1991). Following that, a baseline
blood pressure and pulse was taken and a single oral dose of 200 of modaﬁnil
(Provigil) or placebo (lactose) hidden in identical opaque gelatin capsules was
administered with a small glass of water. Dose selection was based on previous
cognitive studies in healthy volunteers (Turner et al., 2003) and clinical studies in
patients with ADHD (Turner et al., 2004) as well the best recommended therapeutic
dose by the British National Formulary 2010 (www.bnf.org). Peak plasma concen-
trations of modaﬁnil have been obtained 2e3 h after oral administration with an
elimination half-life of 10e12 h (Wong et al., 1998;Müller et al., 2004). Therefore, 2 h
post-drug administration subjects completed the digit span, a reliable battery of
computerised neuropsychological tasks measuring executive function and working
memory, and objective creativity and motivational saliency tasks (see Table 1). The
test battery was performed in ﬁxed order.
2.5. Physiological measures
Blood pressure and pulse measurements were taken using a Criticare Systems
Inc. Comfort Cuff (Model 507NJ) at baseline (0 h), during waiting time (þ1 h),
immediately prior to testing (þ2 h), during a short break (þ3 h) and after completion
of the cognitive test battery (þ4 h).
2.6. Mood rating and task motivation scale
Participants completed visual analogue scales (VAS, Bond and Lader, 1974)
before administration of the drug (baseline) and at intervals during the testing
session: immediately prior to testing (2 h post dosing), 1 h into testing (3 h post
dosing) and on completion of testing (discharge). At each time point subjects were
asked to rate their feeling in terms of 16 dimensions. Themeasures used in this study
were alertedrowsy, calmeexcited, strongefeeble, muzzyeclear headed, well
coordinatedeclumsy, lethargiceenergetic, contentedediscontented, troublede
tranquil, mentally slowequick witted, tenseerelaxed, attentiveedreamy,
incompetenteproﬁcient, happyesad, antagonisticeamicable, interestedebored
and withdrawnegregarious. The dimensions were presented as 100-mm lines, the
two extremes of the emotion (e.g. ‘alert’ and ‘drowsy’) written at each end, and
subjects marked where they felt they ranked on each line. Factors of “alertness”,
“contentedness”, “calmness” and “tranquility” were calculated as proposed by Bond
and Lader (1974) and Herbert et al. (1976).
Task motivation and pleasure was measured using a computerised VAS. After
each task participants were asked “Please rate your feelings on the task you took
today” and had to slide a pointer accordingly on a scale from “0 ¼ not unpleasant” to
“10 ¼ very pleasurable” using a computer mouse.
2.7. Neuropsychological measures
Many of the cognitive measures in this study were drawn from the CANTAB
battery (www.camcog.com) (Sahakian and Owen, 1992; Robbins et al., 1998), but
using novel versions of some of these tasks which included more difﬁcult levels. All
computerised tasks were run on an Advantech personal computer (Model PPC-120T-
RT), and responses were registered either via the touch-sensitive screen or
a response key, depending on the task. A brief description of the key measures for
each of the tasks is presented in Table 1. For full details of each outcomemeasure see
CANTABeclipse (2011) Test Administration Guide.
To measure non-verbal (visuospatial) declarative memory, we used a version of
the CANTAB PAL with an additional level of 12 pattern/location associations (‘Duke
no ceiling’, 12 patterns), and an amended version of the Pattern RecognitionMemory
(PRM) task, which included an additional delayed recognition test after 20 min. For
assessment of verbal and non-verbal working memory, we used forward and
backward digit span from the Wechsler Adult Intelligence Scale (Wechsler, 1981)
and the SWM task from CANTAB with an additional 10-box level. Executive function
was tested by a novel variant of CANTAB tower of London task, the ‘one-touch’
version of the Stockings of Cambridge (SOC) spatial planning task (Owen et al., 1995)
which included a choice of from one to seven; there were, however, no seven move
problems, the most difﬁcult problems were six move.
2.8. Statistical analysis
All data were analysed using the Windows versions of SPSS (Version 15, SPSS,
Chicago). To investigate the effect of experimental treatment on test performance,
differences between group mean performances for single measures were analysed
using one-way analysis of variance (ANOVA) or the equivalent non-parametric
KruskaleWallis ANOVA. Repeated measures ANOVA were used to test the effects
of relevant independent within- and between-subjects variables. To clarify the
Table 1
Summary of neuropsychological and creativity battery.
Task Description Reference Important measures
Working memory
Digit spans A paperepencil test of verbal memory
with immediate recall of digit sequences
of increasing length.
Lezak et al., 2004,
Wechsler, 1981
Maximal span, forward and backward,
total span.
SWM
(4, 6, 8, 10, 12 boxes)
Spatial working memory: a computerised
test of spatial working memory and
strategic search of ‘blue tokens’ hidden
in boxes, problems with 4e12 boxes.
www.camcog.com Total error, between search errors,
within search errors, strategy score.
Planning and
decision making
One-touch Stockings
of Cambridge (SOC)
A computerised test involving planning
a sequence of moves to achieve a goal
arrangement of coloured balls without
moving the balls.
Owen et al., 1995;
www.camcog.com
Mean attempts, overall latency.
Non-verbal
declarative memory
PRM (Immediate
and Delayed)
Pattern Recognition Memory:
a computerised dual-choice test of
abstract visual pattern recognition
with 20 min delay.
Mehta et al., 1999;
www.camcog.com
Percentage correct,
response latency.
PAL (12 Boxes) Paired Associates Memory: delayed
matching of one to twelve shapes to
learnt locations on a touch screen.
Blackwell et al., 2004;
www.camcog.com
Total errors, trials to criterion,
memory score.
Non-verbal creative
problem solving
Group embedded
ﬁgures task (GEFT)
A nonverbal convergent thinking task
requiring subjects to trace a simple shape
within a complex ﬁgure.
Noppe, 1996;
Witkin et al., 2002
Number of correctly identiﬁed shapes.
Line drawing task (LD) Tests of divergent thinking assessing the
generation of associations through line drawings.
Wallach and Kogan,
1965; Claridge
and McDonald, 2009
Total number of responses and
unique responses which no
other participant has given.
Abbreviated Torrance task for adults (ATTA) A task of divergent thinking. Subjects are
given a picture-drawing tasks and are
asked to draw a picture with a title.
Goff, 2002 Scored for ﬂexibility and
elaboration according to
the criteria of Goff.
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modaﬁnil and the effect of placebo were performed where appropriate. All tests
employed one-tailed statistics, threshold at p < 0.05.3. Results
3.1. Demographics
The demographic data are shown in Table 2. The two randomly
assigned groups were matched for age, years of education and
verbal intelligence (as evaluated with the National Adult Reading
Test, NART). For the creativity data, randomization was also
successful and resulted in no statistically signiﬁcant difference
between the groups in terms of creativity baseline scores, verbal IQ
as indexed by the NART, age, gender and years of education
(p > 0.05). Furthermore, there was no signiﬁcant differences
between the number of high and low creativity subjects taking
modaﬁnil or placebo (p > 0.05). The modaﬁnil dose of the study
was well tolerated without side effects or complications. OneTable 2
Mean age, National Adult Reading Test (NART) and formal education for each group.
Values shown are the mean and standard deviation of the mean for each group. Age
is given in years; NART is the predicted verbal IQ score and education level in years in
formal education. ns ¼ not signiﬁcant (P > 0.1).
Placebo Modaﬁnil F value P value
Age (years) 24.6 (3.6) 26.2 (4.2) 2.9 ns
NART IQ 124 (3) 122 (5) 3.1 ns
Education (years) 18.6 (2.5) 19.2 (3.1) 0.6 ns
Gough creativitya 0.9 (0.2) 0.8 (0.2) 3.2 ns
a transformed Creativity baseline measures.volunteer (n ¼ 1 on modaﬁnil) complained about headaches at the
end of the testing session. No other adverse events were reported.
3.2. Physiological effects e blood pressure and pulse
Physiological readings were taken at ﬁve time points during the
experiment. Groups were matched on all physiological measures at
baseline but the analysis was performed on only the last four
physiological measures.
Both systolic and diastolic blood pressure increased over time
(F(3,135) ¼ 7.4, p < 0.001; F(3,135) ¼ 9.0, p < 0.001, respectively)
irrespective of drug treatment Subjects on placebo had higher
systolic blood pressure at the end of the study but when compared
to modaﬁnil this did not reach signiﬁcance (p ¼ 0.4). There was no
effect of drug on diastolic pressure (p ¼ 0.8). Similarly, pulse rate
increased throughout the experiment (F(3,123) ¼ 9.7, p ¼ 0.003)
but modaﬁnil had no effect (P > 0.1).
3.3. One touch Stockings of Cambridge (SOC)
Fig. 1 shows that subjects tested under modaﬁnil made overall
signiﬁcantly fewer attempts to obtain a correct solution relative to
the placebo group (main effect drug: drug by difﬁculty interaction:
F(6,354) ¼ 2.98, p ¼ 0.007). As the ﬁgure indicates this improve-
ment by modaﬁnil was especially large at six moves (Table 3).
A mixed repeated measure analysis of variance using the
number of moves (1e6) as within subject variables and drug
(modaﬁnil vs placebo) as between subject variable was conducted
to investigate the effects of latency in the SOC. Therewas a difﬁculty
effect (F(5,305) ¼ 140.5; p < 0.001) but no drug  difﬁculty inter-
action (F(5,305) ¼ 1.3; p ¼ 0.259) and no main effect of drug
Fig. 1. One-touch Stockings of Cambridge (SOC) spatial planning task mean choice to
correct. Subjects on modaﬁnil made signiﬁcantly fewer choices (p ¼ 0.002) to achieve
the correct answer than those on placebo, particularly at the harder (6 moves). Error
bars represent the SEM.
Table 3
Summary of the test results. Values shown for each variable are the mean and
standard deviation of the mean for each group. The reported p values were derived
from one-way and repeated ANOVAs, as appropriate, performed for all two groups.
Task Placebo
mean (SD)
Modaﬁnil
mean (SD)
P Value
One touch SOC
Mean choice to
correct (6 moves)
1.7 (0.4) 1.4 (0.3) 0.009**
Digit spans
Forward span 6.2 (1.0) 6.5 (1.0) ns
Backward span 4.5 (1.1) 4.7 (1.3) ns
SWM
Between search errors
(10 boxes)
17.2 (16.0) 10.0 (11.3) 0.008**
PRM
Percent correct,
immediate
93.7 (10.2) 94.0 (12.1) ns
Percent correct,
delayed
93.8 (10.3) 98.2 (3.5) 0.036*
PAL
Total errors 19.5 (14.6) 18.1 (16.8) ns
Total trials 10.5 (3.1) 10.2 (3.8) ns
First memory
trial
27.0 (6.2) 27.9 (7.32) ns
Mean memory
to success
3.9 (2.9) 3.6 (3.61) ns
Mean trial
to success
2.1 (0.6) 2.0 (0.7) ns
Stages completed
ﬁrst trial
2.9 (1.0) 2.3 (1.0) ns
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longer tomake their responses especially in themore difﬁcult trials.Measure of
task enjoyment
Pleasurable rating
of tasks (0e10)
2.3 (0.9) 9.0 (0.6) <0.001***
GEFT
Creativity score 5.1 (3.4) 6.5 (3.8) 0.08
LD3.4. Digit spans (Table 3)
There were no signiﬁcant effects of modaﬁnil on digit spans
forward or backward (all p > 0.1).Creativity score 28.5 (11.8) 30.8 (10.5) ns
ATTA
Mean elaboration 2.4 (1.1) 1.9 (0.8) 0.053
Mean ﬂexibility 1.2 (0.3) 1.0 (0.3) 0.057
ATTA¼ Abbreviated Torrance Test for Adults; GET ¼ Group Embedded Figures Task,
LD ¼ Line Drawing; PAL ¼ Paired Associate Learning; PRM ¼ Pattern Recognition
Memory; SOC ¼ Stockings of Cambridge; SWM ¼ Spatial Working Memory;
* ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001. ns ¼ not signiﬁcant (p > 0.1).3.5. Spatial working memory (SWM) (Table 3)
A two way ANOVA found a signiﬁcant effect of drug (F
(1,60) ¼ 7.811, p ¼ 0.007) and a drug  difﬁculty interaction for
between errors (F(1,60) ¼ 8.320, p ¼ 0.005). When analysing the
newly introduced 10-box level there was a signiﬁcant effect of
modaﬁnil (F(1, 61) ¼ 4.179, p ¼ 0.045) with subjects making more
errors in the placebo condition (Fig. 2).3.6. Visual pattern recognition memory (PRM) (Table 3)
For the immediate version of the PRM task, a one way ANOVA
found no signiﬁcant between group differences in number of
correct visual patterns recognised. Furthermore, no signiﬁcant
differences in latency were identiﬁed between groups
(F(2,57) ¼ 0.48, p > 0.05). A one way ANOVA found a signiﬁcant
effect of drug on errors on PRM (F (1,58) ¼ 4.6, p ¼ 0.036). Subjects
receiving modaﬁnil made signiﬁcantly fewer errors in the delayed
PRM than subjects in the placebo group. There were no signiﬁcant
differences in latency between groups (F(1,58) ¼ 4.6, p > 0.05).3.7. Visuospatial paired associates learning (PAL) (Table 3)
A 2 way mixed ANOVA using group (placebo vs modaﬁnil) as
between subject variable and total errors on the PAL shapes (3, 6, 8,
10, 12) as within subject variable was carried out, ﬁnding a signiﬁ-
cant main effect of PAL levels of difﬁculty on total errors
(F(4,244) ¼ 45.8, p < 0.001). There was no main effect of drug
(F(1,61) ¼ 91.3, p ¼ 0.7) and no drug and difﬁculty interaction (F(4,
244) ¼ 0.5, p < 0.71).3.8. Subjective effects (Table 3)
A one way ANOVA found a highly signiﬁcant effect of modaﬁnil
on task motivation (F(1,62) ¼ 1131.6, p < 0.001). Subjects on
modaﬁnil found completing the tasks signiﬁcantly more pleasur-
able (mean ¼ 8.9, SD ¼ 0.6) relative to placebo subjects on all tasks
except for the Group Embedded Figures task (F(1,62)¼ 0.4, p> 0.1).
Subjective measures of contentedness, alertness, tranquillity,
and calmness (p < 0.001) on the Visual Analogue Scale declined
over the session. Subjects in both conditions reported feeling less
contended, alert, tranquil and calm. However, there were no
signiﬁcant effects of drug or drug  time interactions on any of the
self-reported measures (p > 0.1).
3.9. Tests of creativity (Table 3)
We found a non-signiﬁcant trend effect of modaﬁnil on
performance in the Group Embedded Figures Task (F(1,63) ¼ 3.0,
p ¼ 0.08), but no signiﬁcant effect (p > 0.1) in the Line Drawing
Task.
The effects of modaﬁnil on ATTA ﬂexibility scores were inves-
tigated with a one way ANOVA, a main effect of drug (F(1,57) ¼ 4.7,
p¼ 0.036) was observed. Subjects undermodaﬁnil had signiﬁcantly
lower total ﬂexibility scores relative to subjects on placebo.
Fig. 2. Effect of drug on spatial working memory. Subjects on placebo made signiﬁ-
cantly more between search errors on the difﬁcult 10-box problems (p < 0.05). Error
bars represent the SEM.
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investigated with a one way ANOVA and found a trend for main
effects of drug on mean elaboration (F(1,57) ¼ 3.9, p ¼ 0.053) and
total elaboration (F(1,57) ¼ 3.8, p ¼ 0.057). Subjects on modaﬁnil
had signiﬁcantly lower elaboration scores relative to subjects on
placebo. Consistent with the above analysis, there was a main effect
of drug to reduce mean ﬂexibility scores (F(3,55) ¼ 2.9, p ¼ 0.045)
and a trend effect on mean elaboration scores (F(3,55) ¼ 2.8,
p ¼ 0.053).
4. Discussion
Several novel and important ﬁndings have arisen from this
study. Firstly, consistent with our hypothesis, we demonstrated
improvements in performance of non sleep-deprived healthy
volunteers with modaﬁnil on certain tests of ‘cold’ cognition such
as the CANTAB spatial working memory (SWM), ‘one-touch’
Stockings of Cambridge (SOC) and delayed visual pattern recogni-
tion memory (PRM) tasks. Cognitive enhancing effects of modaﬁnil
were only seen for the difﬁcult stages of these computerised tasks.
Of these, the improvement in CANTAB SWM performance is
particularly notable as this is the ﬁrst time that such an effect of
modaﬁnil has been demonstrated in healthy volunteers. There
were less errors after modaﬁnil at both the 10- and 12-box level,
but this reached signiﬁcance only for the 10-box level. This ﬁnding
may be attributed to the use of a new task version with additional
10- and 12-box problems. It is possible that performance was at
ceiling level and thus no improvement could be detected in
previous studies in healthy volunteers which used an easier version
of SWM (Turner et al., 2003) or a version without 10-box problems
(Winder-Rhodes et al., 2010).
This study demonstrates for the ﬁrst time an improvement on
CANTAB pattern recognitionmemory (PRM) delayed recognition. In
contrast, no effects were seen on CANTAB paired associates
learning (PAL). It is possible that, despite having attempted to make
this task more difﬁcult, healthy volunteers still showed ceiling
effects. For example, although in this study there was a 12-box
version of the task, the total errors for the whole test were only
between 18 and 20. In its easier form, this task has been shown to
be sensitive in predicting deﬁcits in patients with mild cognitive
impairment (Swainson et al., 2001), activating a neural circuitry
including the hippocampal formation (de Rover et al., 2011). This
failure by modaﬁnil to affect performance on this typical‘hippocampal’ memory task suggests that the effects of modaﬁnil
on cognition in healthy volunteers are limited and may be related
to actions on speciﬁc neural systems underpinning cognition, such
as fronto-striatal circuitry, which are more obviously associated
with performance on the Tower of London and spatial working
memory tests (Owen et al., 1990). However, the fact that delayed
visual recognition (a typical test of temporal lobe function, Owen
et al., 1995) did show improvement suggests that we should be
cautious in ruling out possible beneﬁcial effects of modaﬁnil on
long-term visual memory.
In the study by Turner et al. (2003) modaﬁnil signiﬁcantly
improved performance in a test of inhibitory control (stop-signal
reaction time task, SSRT), also subsequently observed for patients
with adult attention deﬁcit hyperactivity disorder (Aron et al.,
2003). In addition, modaﬁnil signiﬁcantly slowed performance on
the Stockings of Cambridge Task, whilst improving accuracy of the
solutions. This improvement was interpreted as resulting from
reduced impulsivity; the suppression of over-hastily arrived-at
solutions. However, a subsequent study has successfully dissociated
the performance improving and slowing effects of modaﬁnil on this
task by co-administration of the alpha-1 antagonist prazosin
(Winder-Rhodes et al., 2010). The current study, using a more
difﬁcult form of the task which included 6move solutions found no
signiﬁcant effect of modaﬁnil on latency, but the same improve-
ment for the accuracy measure, representing a second replication
of this result in our laboratory. Therefore, it appears that modaﬁnil
is not simply producing its cognitive enhancing effect through
effects on speed-error trade-off, as originally suggested by Turner
et al. (2003).
This is the ﬁrst study investigating the effects of modaﬁnil on
measures of non-verbal creativity. It is signiﬁcant that modaﬁnil
did not consistently improve performance on these tests of visuo-
spatial or constructive problem solving. It is a limitation of this
study that our tests were restricted to non-verbal creativity.
Another potential limitation of this study is a sample of relatively
high-functioning healthy volunteers, most of them with an
academic background.
It is also important to gauge some of the psychological mecha-
nisms by which modaﬁnil may exert its beneﬁcial effects on
cognition, both in terms of clinical and shift-work related use. An
important ﬁnding of this study is that there was a striking increase
in task motivation. Participants onmodaﬁnil felt considerably more
pleasurable after performing individual tasks assessing ‘cold’
cognition and on all but one of the creativity tasks (the Group
Embedded Task). This ﬁnding is reminiscent of the reinforcing
effects of modaﬁnil in humans described by Stoops et al. (2005)
which were only evident when there were additional cognitive
task demands, suggesting that any motivational effects of the drug
derived mainly from its perceived effects on task performance and
were thus not similar to those of ‘recreational’ drugs of abuse such
as cocaine and amphetamine. The interesting question is whether
modaﬁnil enhances motivation through an hypothesised percep-
tion by the subject of its ability to enhance performance, or alter-
natively whether the drug enhances motivational factors which
directly impact cognition (and both of these may obtain). It should
be noted, however, that modaﬁnil did not produce obvious
subjective effects, for example, on arousal, as indicated by visual
analogue rating scales or cardiovascular measures.
This ﬁnding of motivation enhancing effects of modaﬁnil lends
empirical validity to anecdotal evidence from lifestyle use of
modaﬁnil that the drug improves concentration and enhances the
ability to work for longer periods (Sahakian and Morein-Zamir,
2011). On the other hand, cognitive enhancing effects as
described by recreational users of modaﬁnil have to be carefully
differentiated from placebo effects. So far, no study has
U. Müller et al. / Neuropharmacology 64 (2013) 490e495 495demonstrated cognitive enhancing effects of modaﬁnil in real life
situations outside of laboratory settings.
The main ﬁnding of this study in healthy volunteers is a clear
performance improvement in the most difﬁcult stages of tests of
computerised tests ofworkingmemory, visualmemory andproblem
solving. These and other published ﬁndings suggest that modaﬁnil
can improve alertness and motivation and thus potentially reduce
apathy and improve functional outcome and adherence to treatment
in neuropsychiatric disorders such as substance abuse, depression
and schizophrenia (Blackwell et al., 2004; Turner et al., 2004;
Martínez-Raga et al., 2008; Morgan et al., 2010; Scoriels et al., 2012,
in press). Clinical implications and cognitive enhancing effects
outside of lab settings have to be investigated in future research.
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